Ongoing Clinical Trials for Bladder Transitional Cell Carcinoma Recurrent
This article provides information about ongoing clinical trials for patients with recurrent bladder transitional cell carcinoma. Currently, there is 1 clinical trial investigating new surgical approaches to reduce the risk of cancer returning and improve treatment outcomes. The trial is exploring the use of a light-enhanced surgical technique to more effectively identify and remove bladder tumors.
Clinical trial locations
Study on Hexaminolevulinate for Patients with Non-Muscle Invasive Bladder Cancer to Reduce Need for Second Surgery
This clinical trial is investigating whether a specialized surgical technique can help patients with non-muscle invasive bladder cancer avoid a second surgery while maintaining good treatment results. The study is being conducted in Italy and compares two different approaches to removing bladder tumors.
Main focus and goals: The trial aims to determine if using Photodynamic Trans-urethral Resection of Bladder Tumors (PDD-TURBT) can be as effective as the standard approach while potentially eliminating the need for a second surgery. During PDD-TURBT, doctors use a light-sensitive drug called Hexvix (hexaminolevulinate) that helps them see cancerous tissue more clearly under special lighting. This enhanced visibility may allow surgeons to remove tumors more completely during the first procedure. The study will track whether cancer returns, how quickly any recurrence happens, and how the different surgical methods affect patients’ quality of life and overall costs.
Who can participate: Patients eligible for this trial must be at least 18 years old and have a confirmed diagnosis of non-muscle invasive bladder cancer. They should be candidates for the standard TURBT procedure and potentially need a second surgery according to European treatment guidelines. Importantly, participants must not have received BCG immunotherapy previously (a type of bladder cancer treatment). They also should not have imaging evidence showing that the cancer has spread into the muscle layer or beyond. Patients must be healthy enough to undergo all the procedures required by the study and able to provide written informed consent.
Who cannot participate: The trial excludes patients who have bladder cancer that has invaded the muscle layer or spread beyond the bladder. Patients outside the required age range, those from vulnerable populations who might need special protection, and individuals who don’t meet other specific health requirements cannot join the study.
Treatment approaches being tested: The study involves three different surgical approaches. The experimental method is PDD-TURBT, which uses the Hexvix medication administered directly into the bladder to make cancer cells more visible under special blue light during surgery. This is compared to conventional white-light TURBT followed by a planned second surgery (Re-TURBT) if needed to ensure complete tumor removal. The medication used in PDD-TURBT, hexaminolevulinate, works by accumulating in cancer cells and becoming fluorescent when exposed to blue light, helping surgeons identify and remove all cancerous tissue more thoroughly.
What to expect during the trial: After confirming eligibility and providing consent, participants will be randomly assigned to one of the two surgical approaches. Following the initial surgery, patients will attend follow-up appointments starting at 3 months to check for any cancer recurrence. Additional monitoring visits will occur at 4.5 months to assess for late recurrences and disease progression. Throughout the study, researchers will evaluate various aspects of health and quality of life. The trial is expected to continue until July 2027.
Summary
Currently, there is one active clinical trial for patients with recurrent bladder transitional cell carcinoma, taking place in Italy. This trial focuses on improving surgical outcomes by using photodynamic diagnosis technology with the drug Hexvix (hexaminolevulinate) to enhance tumor visibility during removal. The study represents an important effort to reduce the need for multiple surgeries while maintaining effective cancer treatment. Patients interested in participating should discuss with their healthcare providers whether they meet the eligibility criteria and whether this trial might be an appropriate treatment option for their specific situation.